Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Research Square
|
February 23, 2026
Targeting PFKFB3 to enhance CDK4/6 inhibitor response in ER+ breast cancer
Sucheta Telang, Brian F Clem, Ariamna A Herrera Miret, et al.
Cell Stem Cell
|
April 4, 2009
Mouse fibroblasts lacking RB1 function form spheres and undergo reprogramming to a cancer stem cell phenotype
Yongqing Liu, Brian Clem, Ewa K Zuba-Surma, et al.
Molecular Cancer Therapeutics
|
January 19, 2008
Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth
Brian Clem, Sucheta Telang, Amy Clem, et al.
Molecular Cancer
|
August 25, 2012
Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth
Sucheta Telang, Kristin K Nelson, Deanna L Siow, et al.
The Journal of Biological Chemistry
|
December 2, 2009
Disruption of inducible 6-phosphofructo-2-kinase ameliorates diet-induced adiposity but exacerbates systemic insulin resistance and adipose tissue inflammatory response
Yuqing Huo, Xin Guo, Honggui Li, et al.
Molecular Cancer Therapeutics
|
May 16, 2013
Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer
Brian F Clem, Julie O'Neal, Gilles Tapolsky, et al.
Nature Communications
|
December 2, 2014
Different thresholds of ZEB1 are required for Ras-mediated tumour initiation and metastasis
Yongqing Liu, Xiaoqin Lu, Li Huang, et al.
International Journal of Cancer
|
September 19, 2018
Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers
Susmita Mondal, Debarshi Roy, Sayantani Sarkar Bhattacharya, et al.
Journal of Perinatology : Official Journal of the California Perinatal Association
|
April 16, 2026
Temporal trends in outcomes for infants with neonatal opioid withdrawal managed with the Finnegan scoring tool: Insights from the INFORM NOW Study
Lori A Devlin, Walter K Kraft, Denise C Babineau, et al.
BMC Cancer
|
December 15, 2011
Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma
Sucheta Telang, Mary Ann Rasku, Amy L Clem, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Research Square
|
February 23, 2026
Targeting PFKFB3 to enhance CDK4/6 inhibitor response in ER+ breast cancer
Sucheta Telang, Brian F Clem, Ariamna A Herrera Miret, et al.
Cell Stem Cell
|
April 4, 2009
Mouse fibroblasts lacking RB1 function form spheres and undergo reprogramming to a cancer stem cell phenotype
Yongqing Liu, Brian Clem, Ewa K Zuba-Surma, et al.
Molecular Cancer Therapeutics
|
January 19, 2008
Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth
Brian Clem, Sucheta Telang, Amy Clem, et al.
Molecular Cancer
|
August 25, 2012
Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth
Sucheta Telang, Kristin K Nelson, Deanna L Siow, et al.
The Journal of Biological Chemistry
|
December 2, 2009
Disruption of inducible 6-phosphofructo-2-kinase ameliorates diet-induced adiposity but exacerbates systemic insulin resistance and adipose tissue inflammatory response
Yuqing Huo, Xin Guo, Honggui Li, et al.
Molecular Cancer Therapeutics
|
May 16, 2013
Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer
Brian F Clem, Julie O'Neal, Gilles Tapolsky, et al.
Nature Communications
|
December 2, 2014
Different thresholds of ZEB1 are required for Ras-mediated tumour initiation and metastasis
Yongqing Liu, Xiaoqin Lu, Li Huang, et al.
International Journal of Cancer
|
September 19, 2018
Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers
Susmita Mondal, Debarshi Roy, Sayantani Sarkar Bhattacharya, et al.
Journal of Perinatology : Official Journal of the California Perinatal Association
|
April 16, 2026
Temporal trends in outcomes for infants with neonatal opioid withdrawal managed with the Finnegan scoring tool: Insights from the INFORM NOW Study
Lori A Devlin, Walter K Kraft, Denise C Babineau, et al.
BMC Cancer
|
December 15, 2011
Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma
Sucheta Telang, Mary Ann Rasku, Amy L Clem, et al.
Page
of 5